Texas Yale Capital Corp’s Novo Nordisk NVO Stock Holding History

Texas Yale Capital Corp’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	22,899 +575	+3%	+$24.7K	0.02%	288
2026 Q1	$820K	Buy	22,324 +675	+3%	+$32K	0.02%	317
2025 Q4	$1.1M	Sell	21,649 -847	-4%	-$43.3K	0.03%	268
2025 Q3	$1.25M	Sell	22,496 -1,195	-5%	-$69.9K	0.04%	240
2025 Q2	$1.64M	Buy	23,691 +650	+3%	+$44.2K	0.05%	208
2025 Q1	$1.6M	Sell	23,041 -10,180	-31%	-$841K	0.07%	210
2024 Q4	$2.86M	Sell	33,221 -1,605	-5%	-$174K	0.11%	142
2024 Q3	$4.15M	Buy	34,826 +585	+2%	+$78K	0.18%	95
2024 Q2	$4.89M	Buy	34,241 +945	+3%	+$125K	0.23%	79
2024 Q1	$4.28M	Buy	33,296 +146	+0.4%	+$17.4K	0.19%	86
2023 Q4	$3.43M	Buy	33,150 +226	+0.7%	+$22.4K	0.16%	100
2023 Q3	$2.99M	Hold	32,924	–	–	0.14%	101
2023 Q2	$2.66M	Hold	32,924	–	–	0.13%	126
2023 Q1	$2.62M	Hold	32,924	–	–	0.13%	125
2022 Q4	$2.23M	Hold	32,924	–	–	0.13%	143
2022 Q3	$1.64M	Hold	32,924	–	–	0.11%	171
2022 Q2	$1.83M	Hold	32,924	–	–	0.12%	161
2022 Q1	$1.83M	Hold	32,924	–	–	0.1%	182
2021 Q4	$1.84M	Hold	32,924	–	–	0.09%	182
2021 Q3	$1.58M	Hold	32,924	–	–	0.09%	195
2021 Q2	$1.38M	Hold	32,924	–	–	0.08%	204
2021 Q1	$1.11M	Hold	32,924	–	–	0.07%	218
2020 Q4	$1.15M	Hold	32,924	–	–	0.08%	213
2020 Q3	$1.14M	Hold	32,924	–	–	0.09%	197
2020 Q2	$1.08M	Sell	32,924 -14,950	-31%	-$477K	0.09%	205
2020 Q1	$1.44M	Hold	47,874	–	–	0.14%	143
2019 Q4	$1.39M	Hold	47,874	–	–	0.09%	204
2019 Q3	$1.24M	Hold	47,874	–	–	0.09%	208
2019 Q2	$1.22M	Sell	47,874 -47,874	-50%	-$1.18M	0.09%	212
2019 Q1	$2.5M	Buy	95,748 +47,874	+100%	+$1.18M	0.1%	200
2018 Q4	$1.1M	Hold	47,874	–	–	0.1%	199
2018 Q3	$1.13M	Hold	47,874	–	–	0.09%	214
2018 Q2	$1.1M	Hold	47,874	–	–	0.09%	203
2018 Q1	$1.18M	Hold	47,874	–	–	0.1%	193
2017 Q4	$1.28M	Hold	47,874	–	–	0.11%	184
2017 Q3	$1.15M	Hold	47,874	–	–	0.1%	192
2017 Q2	$1.03M	Hold	47,874	–	–	0.09%	202
2017 Q1	$821K	Hold	47,874	–	–	0.07%	243
2016 Q4	$858K	Hold	47,874	–	–	0.08%	226
2016 Q3	$996K	Hold	47,874	–	–	0.1%	194
2016 Q2	$1.29M	Hold	47,874	–	–	0.13%	148
2016 Q1	$1.3M	Hold	47,874	–	–	0.13%	135
2015 Q4	$1.39M	Hold	47,874	–	–	0.13%	124
2015 Q3	$1.3M	Sell	47,874 -1,700	-3%	-$48.1K	0.12%	141
2015 Q2	$1.36M	Buy	49,574 +300	+0.6%	+$8.43K	0.11%	152
2015 Q1	$1.31M	Buy	49,274 +650	+1%	+$15K	0.11%	160
2014 Q4	$1.03M	Buy	48,624 +500	+1%	+$11.2K	0.09%	184
2014 Q3	$1.15M	Buy	48,124 +21,674	+82%	+$499K	0.11%	138
2014 Q2	$611K	Sell	26,450 -4,550	-15%	-$100K	0.08%	223
2014 Q1	$708K	Hold	31,000	–	–	0.1%	175
2013 Q4	$573K	Hold	31,000	–	–	0.09%	170
2013 Q3	$525K	Hold	31,000	–	–	0.09%	177
2013 Q2	$480K	Buy	+31,000	New	+$516K	0.08%	175

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Texas Yale Capital Corp's NVO Position: Q2 2026 in Review

Texas Yale Capital Corp increased its Novo Nordisk (NVO) stake by 2.6% in Q2 2026, buying an estimated $24.7K and bringing the position to 22,899 shares worth $1.1M. The position accounts for 0.02% of the portfolio, ranked #288.

Texas Yale Capital Corp first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.89M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Texas Yale Capital Corp held 22,899 shares of Novo Nordisk worth $1.1M as of Q2 2026.
Texas Yale Capital Corp bought 575 Novo Nordisk shares in Q2 2026, an estimated $24.7K.
Novo Nordisk made up 0.02% of Texas Yale Capital Corp's portfolio in Q2 2026, its #288 holding.
Texas Yale Capital Corp first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Texas Yale Capital Corp's Novo Nordisk position peaked at $4.89M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Texas Yale Capital Corp's 13F filing for Q2 2026, filed 12 Aug 2026.